PA
TVTX icon

Parallel Advisors’s Travere Therapeutics TVTX Stock Holding History

Parallel Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Hold
2,707
– – ﹤0.01% 1437
2026
Q1 		$80.4K Sell
2,707
-1,078
-28% -$32.2K ﹤0.01% 1715
2025
Q4 		$145K Buy
3,785
+3,003
+384% +$97.6K ﹤0.01% 1256
2025
Q3 		$18.7K Buy
782
+400
+105% +$7.52K ﹤0.01% 2280
2025
Q2 		$5.65K Hold
382
– – ﹤0.01% 2697
2025
Q1 		$6.84K Hold
382
– – ﹤0.01% 2575
2024
Q4 		$6.65K Hold
382
– – ﹤0.01% 2536
2024
Q3 		$5.34K Hold
382
– – ﹤0.01% 2586
2024
Q2 		$3.14K Buy
382
+95
+33% +$640 ﹤0.01% 2670
2024
Q1 		$2.21K Hold
287
– – ﹤0.01% 2799
2023
Q4 		$2.58K Buy
+287
New +$2.09K ﹤0.01% 2725
2022
Q4 		– Sell
-41
Closed -$1K – 3524
2022
Q3 		$1K Buy
41
+37
+925% +$956 ﹤0.01% 3030
2022
Q2 		$0 Buy
+4
New +$101 ﹤0.01% 3367
2020
Q4 		– Sell
-94
Closed -$2K – 2725
2020
Q3 		$2K Hold
94
– – ﹤0.01% 2352
2020
Q2 		$1K Buy
+94
New +$1.5K ﹤0.01% 2377
2017
Q3 		– Sell
-10
Closed – – 2215
2017
Q2 		$0 Buy
+10
New +$181 ﹤0.01% 2211

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's TVTX Position: Q2 2026 in Review

Parallel Advisors held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 2,707 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1437.

Parallel Advisors first reported a position in TVTX in Q2 2017 and has held it in 16 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Parallel Advisors held 2,707 shares of Travere Therapeutics worth $154K as of Q2 2026.
  • Parallel Advisors left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1437 holding.
  • Parallel Advisors first reported a position in Travere Therapeutics in Q2 2017 and has held it in 16 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.